MarginsXMarginsX
Home › Markets › Health Care › CBIO

Crescent Biopharma Inc. (CBIO)

CBIO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$13.50
-4.59% on the day
Market cap
$525.1M
Small cap
Revenue · 2025
$10.8M
Prior year not contiguous
Net income · 2025
-$153.9M
-1419.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1253689/000162828026011983/0001628280-26-011983-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCBIO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2014
SEC CIK0001253689
SEC industry codePharmaceutical Preparations
Incorporated inCayman Islands

Financials · 2025

LineValue
Revenue$10.8M
Net income-$153.9M
Operating income-$152.6M
Net margin-1419.6%
Operating margin-1407.5%
Revenue growthNo prior-year revenue to compare
Cash$213.2M
Total assets$240.3M
P/E (computed)Net income was not positive
P/S (computed)48.4×

Warning signs

Cash runway
42.3 months
$289.4M cash at September 30, 2026
Share count, 1 year
+180.0%
2025-11-03 to 2026-11-11 · +5940.3% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$29.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$289.4M cash; operating cash flow -$20.5M a quarter.Report 2026-09-30
Shares outstanding38,895,442 (2026-11-11); 13,892,516 a year earlier; 64,393,294 three years earlier. 3y figure adjusted for split (1-for-100 overall).Cover page 2026-11-11
Reverse splits, 3 years1; latest 1-for-100 on 2025-06-16Source 2025-06-16
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-07-15
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United States; changed auditors 1 time in 24 months8-K 4.01 2025-06-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $30.6M, sold $1.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$3.1M-$37.7M-$26.9M$289.4MNo debt tags$15.0M10-Q 2026-11-12
Q2 2026
2026-06-30
$0-$24.8M-$19.5M$171.6MNo debt tags$11.9M10-Q 2026-07-30
Q1 2026
2026-03-31
$1.0M-$23.3M-$8.9M$189.2MNo debt tags$11.9M10-Q 2026-04-29
Q4 2025
2025-12-31
$10.8M-$23.3M-$26.7M$213.2MNo debt tags$10.8M10-K 2026-02-26
Q3 2025
2025-09-30
$0-$24.6M-$17.5M$133.3MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
$0-$21.8M-$16.4M$152.6MNo debt tagsNeeds four quarters10-Q 2026-07-30
Q1 2025
2025-03-31
$0-$15.1M-$10.9M$22.4MNo debt tagsNeeds four quarters10-Q 2026-04-29
Q4 2024
2024-12-31
Not filed-$7.2M-$3.7M$34.8MNo debt tagsNeeds four quarters10-K 2025-02-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentPOS AM2026-07-30
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-21

Source: SEC EDGAR submissions feed, 682 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+4.5%
1 month+9.6%
3 months-14.9%
Year to date+19.3%
1 year+9.0%
From 52-week high-47.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
INDPIndaptus Therapeutics Inc.$3.45+8.83%$529.9M
GYREGyre Therapeutics Inc.$4.39+1.86%$506.3M
ZVRAZevra Therapeutics Inc.$9.25+1.87%$550.4M
EVOEvotec SE$1.56-1.27%$555.0M
HELPHelus Pharma Inc.$7.67-13.53%$560.4M
MNPRMonopar Therapeutics Inc.$71.97-0.04%$487.7M
WVEWave Life Sciences Inc.$2.87-8.31%$566.0M
CAPRCapricor Therapeutics Inc.$8.30-12.91%$482.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier